jueves, 8 de octubre de 2020

FDA probing whether Intercept Pharma drug is tied to risk of liver injury

FDA probing whether Intercept Pharma drug is tied to risk of liver injury

Daily Recap

STAT Plus: FDA investigating whether Intercept Pharma drug is tied to potential liver injury risk

By ADAM FEUERSTEIN


HYACINTH EMPINADO/STAT
The company disclosed the inquiry in several new sentences added deep in an existing risk-statement section of a quarterly report.

No hay comentarios: